Search results for "colorectal carcinoma"

showing 10 items of 25 documents

Oleocanthal exerts antitumor effects on human liver and colon cancer cells through ROS generation

2017

The beneficial health properties of the Mediterranean diet are well recognized. The principle source of fat in Mediterranean diet is extra-virgin olive oil (EVOO). Oleocanthal (OC) is a naturally occurring minor phenolic compound isolated from EVOO, which has shown a potent anti-inflammatory activity, by means of its ability to inhibit the cyclooxygenase (COX) enzymes COX-1 and COX-2. A large body of evidence indicates that phenols exhibit anticancer activities. The aim of the present study was to evaluate the potential anticancer effects of OC in hepatocellular carcinoma (HCC) and colorectal carcinoma (CRC) models. A panel of human HCC (HepG2, Huh7, Hep3B and PLC/PRF/5) and CRC (HT29, SW48…

0301 basic medicineCancer ResearchCarcinoma HepatocellularHepatocellular carcinomaOleocanthalExtra-virgin olive oilCellApoptosisCyclopentane Monoterpenes03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePhenolsOleocanthalmedicineHumansCyclooxygenase InhibitorsViability assayOlive OilCaspaseCell ProliferationAldehydesbiologyCell growthLiver NeoplasmsApoptosiHep G2 CellsCell cycledigestive system diseasesColorectal carcinoma030104 developmental biologymedicine.anatomical_structureOncologychemistryApoptosisCell culture030220 oncology & carcinogenesisImmunologybiology.proteinCancer researchReactive oxygen specieColorectal NeoplasmsReactive Oxygen SpeciesDNA DamageInternational Journal of Oncology
researchProduct

Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX.

2017

IF 6.029; International audience; BackgroundThe prognostic value of lymphocyte infiltration (LI) of colorectal carcinoma (CC) has been demonstrated by several groups. However, no validated test is currently available for clinical practice. We previously described an automated and reproducible method for testing LI and aimed to validate it for clinical use.Patients and methodsAccording to National Institutes of Health criteria, we designed a prospective validation of this biomarker in patients included in the PETACC8 phase III study. Primary objective was to compare percentage of patients alive and without recurrence at 2 years in patients with high versus low LI (#NCT02364024). Associations…

0301 basic medicineOncologyMaleCancer ResearchOrganoplatinum CompoundsColorectal cancermedicine.medical_treatmentMedizinLeucovorinProspective cohort study[ SDV.CAN ] Life Sciences [q-bio]/Cancer0302 clinical medicineFOLFOXOrganoplatinum Compounds/therapeutic useAntineoplastic Combined Chemotherapy ProtocolstudyLymphocytesProspective StudiesProspective cohort studyLeucovorin/therapeutic useMiddle AgedPrognosis3. Good healthColorectal carcinomaOncologyFluorouracil030220 oncology & carcinogenesisPredictive value of testsColonic NeoplasmsBiomarker (medicine)Lymphocytes/pathologyFemaleFluorouracilAdjuvantmedicine.drugAdultmedicine.medical_specialty[SDV.CAN]Life Sciences [q-bio]/CancerFluorouracil/therapeutic useBiomarkers Tumor/analysis03 medical and health sciencesLymphocytes Tumor-InfiltratingPredictive Value of TestsBiomarker; Colorectal carcinoma; Immune response; Prospective cohort study; Oncology; Cancer ResearchInternal medicinemedicineBiomarkers TumorHumansImmune responseSurvival analysisAgedbusiness.industryBiomarkermedicine.diseaseSurvival AnalysisSurgery030104 developmental biologyProspective cohort&nbspMultivariate AnalysisColonic Neoplasms/diagnosisAntineoplastic Combined Chemotherapy Protocols/therapeutic usebusiness
researchProduct

The liquid biopsy in the management of colorectal cancer patients: Current applications and future scenarios.

2018

The term liquid biopsy refers to the analysis of biomarkers in any body fluid, including blood, urine and cerebrospinal fluid. In cancer, liquid biopsy testing allows the analysis of tumor-derived DNA, RNA, miRNA and proteins that can be either cell-free or contained in circulating tumor cells (CTC), extracellular vesicles (EVs) or platelets. A number of studies suggest that liquid biopsy testing could have a relevant role in the management of colorectal cancer (CRC) patients at different stages of the disease. Analysis of cell-free DNA (cfDNA), CTC and/or miRNA can provide relevant information for the early diagnosis of CRC and the identification of minimal residual disease and, more gener…

0301 basic medicineOncologymedicine.medical_specialtyColorectal cancerDiseaseColorectal NeoplasmPredictivePrognosticSomatic evolution in cancer03 medical and health sciences0302 clinical medicineCirculating tumor cellInternal medicinemedicineCell-Free Nucleic AcidBiomarkers TumorHumansRadiology Nuclear Medicine and imagingLiquid biopsybusiness.industryLiquid BiopsyCancerDisease ManagementGeneral MedicineBiomarkerDNA Neoplasmmedicine.diseaseMinimal residual disease3. Good healthColorectal carcinoma030104 developmental biologyOncology030220 oncology & carcinogenesisBiomarker (medicine)businessColorectal NeoplasmsCell-Free Nucleic AcidsHumanCancer treatment reviews
researchProduct

Clinical relevance of thymidylate syntetase expression in the signet ring cell histotype component of colorectal carcinoma

2004

Thymidylate Synthase (TS) is the key enzyme for DNA synthesis pathways and is inhibited by 5-fluorouracil (5FU). The aim of this work was to study TS expression and the proliferation rate in the different histological types of colorectal carcinoma (CRC). 50 patients with CRC were included in this study and evaluated immunohistochemically using the monoclonal antibodies, TS106 and Ki67. 20 tumours were of the intestinal type, 15 cases were signet ring cell carcinoma (SRCCs) and 15 cases were "mixed-type", with at least two different histological components. Intestinal and mucinous histotypes were positive for TS and Ki67, while "signet ring cell" samples were negative or showed only weak and…

AdultMaleCancer ResearchPathologymedicine.medical_specialtyProliferation indexColorectal cancerSettore MED/08 - Anatomia PatologicaThymidylate synthase expressionThymidylate synthaseSignet ring cell carcinomaSignet ring cell carcinomaCarcinomamedicineHumansThymidylate synthase expression; Signet ring cell carcinoma; Colorectal carcinoma; ImmunohistochemistryAgedbiologySignet ring cellThymidylate SynthaseMiddle AgedCell cyclemedicine.diseaseImmunohistochemistrydigestive system diseasesNeoplasm ProteinsColorectal carcinomaKi-67 AntigenOncologybiology.proteinCancer researchSettore BIO/14 - FarmacologiaImmunohistochemistryFemaleColorectal NeoplasmsCarcinoma Signet Ring Cell
researchProduct

Randomized Multicenter Phase II Trial of Two Different Schedules of Irinotecan Combined with Capecitabine as First-Line Treatment in Metastatic Color…

2004

BACKGROUND The aim of the current randomized Phase II study was to investigate the efficacy and safety of capecitabine combined with irinotecan as first-line treatment in metastatic colorectal carcinoma (CRC). METHODS A total of 140 patients received capecitabine at a dose of 1250 mg/m2 twice daily on Days 2–15 and irinotecan at a dose of either 300 mg/m2 on Day 1 (Arm A) or 150 mg/m2 on Days 1 and 8 (Arm B) every 3 weeks. During the course of the study, enrollment was continued using lower doses of capecitabine (1000 mg/m2 twice daily) and irinotecan (Arm A: 240 mg/m2; Arm B: 120 mg/m2) to improve the safety profile of the combinations. RESULTS Efficacy was evaluable in 134 patients (68 in…

AdultMaleCancer Researchmedicine.medical_specialtyColorectal cancerPhases of clinical researchCOLON CANCERIrinotecanGastroenterologyDeoxycytidineDrug Administration Schedulecolorectal carcinoma first-line treatment irinotecan and capecitabine combination Phase II triallaw.inventionCapecitabineRandomized controlled triallawInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansNeoplasm MetastasisAdverse effectCapecitabineAgedXELIRIbusiness.industryCarcinomaCancerMiddle Agedmedicine.diseaseSurgeryIrinotecanOncologyDrug EvaluationCamptothecinFemaleFluorouracilbusinessColorectal Neoplasmsmedicine.drug
researchProduct

Epidemiological, clinical and molecular characterization of Lynch‐like syndrome: A population‐based study

2019

Colorectal carcinomas that are mismatch repair (MMR)‐deficient in the absence of MLH1 promoter methylation or germline mutations represent Lynch‐like syndrome (LLS). Double somatic events inactivating MMR genes are involved in the etiology of LLS tumors. Our purpose was to define the clinical and broader molecular hallmarks of LLS tumors and the population incidence of LLS, which remain poorly characterized. We investigated 762 consecutive colorectal carcinomas operated in Central Finland in 2000–2010. LLS cases were identified by a stepwise protocol based on MMR protein expression, MLH1 methylation and MMR gene mutation status. LLS tumors were profiled for CpG Island Methylator Phenotype (…

Cancer ResearchMICROSATELLITE INSTABILITYDNA mismatch repairMISMATCH-REPAIR DEFICIENCYGene mutationmedicine.disease_cause0302 clinical medicinelynch syndromeFinlandMolecular Epidemiologyeducation.field_of_studyMutationISLAND METHYLATOR PHENOTYPENONPOLYPOSIS COLORECTAL-CANCERlynch-like syndromeTUMORSLynch syndrome3. Good healthOncology030220 oncology & carcinogenesissyöpätauditColorectal NeoplasmsMutL Protein Homolog 1Lynch-like syndromeAdult3122 CancersPopulationsuolistosyövätCpG island methylator phenotypeBiologyta3111FREQUENCYMLH103 medical and health sciencesGermline mutationcolorectal carcinomaBRAF MUTATIONCOLONmedicineHumansLynchin oireyhtymäeducationneoplasmsMSIAgedRetrospective StudiesCpG Island Methylator PhenotypeMicrosatellite instabilityDNASOMATIC MUTATIONSta3122CpG Island Methylator phenotypemedicine.diseaseColorectal Neoplasms Hereditary Nonpolyposisdigestive system diseasesCOPY NUMBERMutationCancer researchInternational Journal of Cancer
researchProduct

The Natural Fungal Metabolite Beauvericin Exerts Anticancer Activity In Vivo: A Pre-Clinical Pilot Study

2017

Recently, in vitro anti-cancer properties of beauvericin, a fungal metabolite were shown in various cancer cell lines. In this study, we assessed the specificity of this effect by comparing beauvericin cytotoxicity in malignant versus non-malignant cells. Moreover, we tested in vivo anticancer effects of beauvericin by treating BALB/c and CB-17/SCID mice bearing murine CT-26 or human KB-3-1-grafted tumors, respectively. Tumor size and weight were measured and histological sections were evaluated by Ki-67 and H/E staining as well as TdT-mediated-dUTP-nick-end (TUNEL) labeling. Beauvericin levels were determined in various tissues and body fluids by LC-MS/MS. In addition to a more pronounced …

Cell SurvivalColonlcsh:MedicineAntineoplastic AgentsPilot ProjectsMice SCIDKidneyFecescolorectal carcinomaCell Line TumorDepsipeptidesNeoplasmsAnimalsHumansTissue Distributionddc:610Aspartate AminotransferasesMice Inbred BALB CtherapyCommunicationbeauvericinlcsh:RcyclohexadepsipeptideAlanine TransaminaseTumor BurdenAdipose TissueLivercervix carcinomaToxins
researchProduct

Distinct biological effects are observed in HT-29 colorectal carcinoma cells induced to express K-RASG12V or K-RASG13D

2015

KRAS Colorectal carcinoma Cetuximab
researchProduct

Molecular detection of TP53, Ki-Ras and p16INK4A promoter methylation in plasma of patients with colorectal cancer and its association with prognosis…

2006

BACKGROUND:Despite the improvement in detection and surgical therapy in the last years, the outcome of patients affected by colorectal carcinoma (CRC) remains limited by metastatic relapse. The aim of this study was to investigate the presence of free tumor DNA in the plasma of CRC patients in order to understand its possible prognostic role. PATIENTS AND METHODS: Ki-Ras, TP53 mutations and p16(INK4A) methylation status were prospectively evaluated in tumor tissues and plasma of 66 CRC patients. RESULTS: In 50 of the 66 primitive tumor cases (76%) at least one significant alteration was identified in Ki-Ras and/or TP53 and/or p16(INK4A) genes. Eighteen of the 50 patients presented the same …

MaleOncologymedicine.medical_specialtySettore MED/06 - Oncologia MedicaColorectal cancerColorectal carcinoma Free-cell DNA Ki-Ras TP53DiseasePolymerase Chain ReactionInternal medicinePromoter methylationHumansMedicineProspective StudiesPromoter Regions GeneticProspective cohort studyneoplasmsPolymorphism Single-Stranded ConformationalAgedNeoplasm StagingP16 geneUnivariate analysisbusiness.industryGenes p16DNA NeoplasmHematologyMethylationDNA MethylationGenes p53Prognosismedicine.diseaseGenes rasOncologyCell-free fetal DNAFemaleColorectal NeoplasmsbusinessAnnals of Oncology
researchProduct

Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated w…

2002

Background: K-ras mutations, one of the earliest events observed in colorectal carcinogenesis, are mostly found in codons 12 and 13, and less frequently in codon 61, all three of which are estimated to be critical for the biological activity of the protein. Nevertheless the prognostic significance of such mutations remains controversial. Our purpose was to assess whether any or specific K-ras mutations in primary colorectal cancer had prognostic significance and were linked to clinico-pathological parameters. Patients and methods: Paired tumor and normal tissue samples from a consecutive series of 160 untreated patients (median of follow up 71 months), undergoing resective surgery for prima…

MaleSettore MED/06 - Oncologia MedicaColorectal cancermedicine.disease_causePolymerase Chain ReactionMetastasisProspective StudiesMutationTransition (genetics)Biopsy NeedleDNA NeoplasmHematologyMiddle AgedFlow CytometryPrognosisColorectal carcinomaOncologyFemaleColorectal NeoplasmsAdultGenetic Markersmedicine.medical_specialtyK-ras mutationAdenocarcinomaSensitivity and SpecificityPredictive Value of TestsCulture TechniquesInternal medicineCarcinomamedicineHumansCodonGeneAgedNeoplasm StagingProbabilityProportional Hazards ModelsAnalysis of VarianceProportional hazards modelbusiness.industrymedicine.diseaseDNA ploidyGenes rasLogistic ModelsEndocrinologyGenetic markerMultivariate AnalysisMutationCancer researchbusinessAnnals of Oncology
researchProduct